Introduction
The standard therapy for acute symptomatic anemia is allogeneic blood transfusion. Critical anemia with a hemoglobin (Hb) level of <5 g/dL, compromises the oxygen-carrying capacity of blood, leading to tissue ischemia and worsening outcomes (1) (2) (3) . This effect is magnified in patients with underlying cardiac disease, renal disease, advanced age, and traumatic injuries (4, 5) .
In today's society, physicians encounter patients with different ideological and religious beliefs that may interfere with traditional medical management. This dilemma frequently arises with Jehovah's Witness patients because transfusions of blood products are not permitted. This may be detrimental because every 1-g/dL decrease in Hb concentration <8 g/dL increases the odds of death 2.5 fold (6) . Consequently, in this population, alternative solutions to blood transfusions include agents such as Hb-based oxygen carriers (HBOCs).
The search for a safe and readily available blood substitute has been under way for decades. HBOC (HbO 2 Therapeutics, Souderton PA), is a highly purified, polymerized bovine Hb product with an oxygen-carrying capacity (1.26 mL O 2 /g Hb) similar to that of red blood cells (RBCs) (7, 8) . The low endotoxin and phospholipid specifications for HBOC-201 eliminate the contaminantrelated toxicities and complications of earlier generation HBOCs (1.5, 9) . Each unit of HBOC-201 contains 32.5 g of Hb; does not require cross-matching; is sterile, readily accessible, and stable at room temperature for up to 3 years; and has a half-life of 19 h in circulation (3). This case report describes a Jehovah's Witness recipient of a kidney-pancreas transplant with critical postoperative anemia who was resuscitated with HBOC-201. This is the first report of HBOC-201 for the management of severe anemia in an organ transplant recipient and the first use of any HBOC in a recipient of double solid organ transplant surgery.
Case Report
The patient was a 46-year-old Jehovah's Witness man with a history of type 1 diabetes since age 5, complicated with retinopathy, neuropathy, gastroparesis, hypertension, nephropathy, and intermittent hemodialysis while waiting for a donor kidney and pancreas. In November 2015, a donor became available, and the patient was informed about the risk of death due to bleeding because, as Jehovah's Witness, blood transfusion was not an option. The surgery was uneventful, with minimal blood loss and good hemostasis. His pretransplant laboratory values were Hb concentration of 9 g/dL and hematocrit of 27%. The immediate postoperative laboratory work indicated a Hb concentration of 8.2 g/dL, hematocrit of 23.4%, and creatinine of 4.55 mg/dL.
On postoperative day (POD) 2, splenic vein thrombosis was noticed. Therapeutic heparin infusion was started to prevent thrombus expansion and graft compromise. Bloodless surgery protocols were in place and included limited phlebotomies, use of pediatric blood tubes, and efforts to limit hemodilution. In addition, the patient was administered daily vitamin C, ferrous sucrose, and folic acid, together with 10 000 U of epoetin alfa to enhance production of RBCs. On POD 3, Hb levels fell to 6.8 g/ dL. Sonography showed a large intra-abdominal fluid collection consistent with a hematoma. Heparin infusion was stopped. Patient symptoms, including tachycardia and tachypnea, indicated decreased oxygen delivery, which was addressed via inspired oxygen supplementation. By day 4, his Hb level had decreased to 6 g/dL and his oxygen requirements had further increased. The patient was intubated and mechanically ventilated to further reduce oxygen demand. Simultaneously, the U.S. Food and Drug Administration, HbO 2 Therapeutics, and the local institutional review board granted permission for compassionate use of HBOC-201 under Title 21 of the Code of Federal Regulations for emergency or compassionate use (3). On POD 5, when the Hb concentration decreased to 2.0 g/dL, HBOC-201 infusion was initiated and continued to maintain total Hb (THb) at 6 g/dL (Figure 1 ). HBOC-201 (1 U = 250 mL) was infused over a 4-h period, and the need for additional units was assessed daily. During the following week, the patient remained mechanically ventilated; however, oxygen supplementation was gradually decreased from 100% to 40%, and his tachycardia improved. By POD 10, he had received 10 U of HBOC-201, and THb had increased from 2.0 to 6.8 g/dL (native Hb 6 g/dL). On PODs 11 and 12, the patient received an additional 2 U of HBOC-201 to maintain THb at 6 g/dL.
The patient displayed known side effects of HBOC-201, including elevated arterial blood pressure (after 3 U of HBOC-201), elevated methemoglobin (metHb) concentration, and pulse oximetry desaturation. These side effects were successfully mitigated with the use of nicardipine drip, methylene blue administration, and confirmation of actual oxygen saturation with arterial blood gas, respectively. The metHb concentration began to increase soon after the onset of HBOC-201 administration and peaked at 22% after 10 U were administered ( Figure 2 ). By POD 17, native Hb concentration was stable at 6.8 g/dL, and the patient was extubated.
On the following days, the patient's condition continued to improve. He was alert, participating in physical therapy, and tolerating his assigned diet. By POD 22, his native Hb concentration had increased to 8.8 g/dL and creatinine had decreased to 0.8 mg/dL. The patient was discharged home on POD 29 and scheduled for clinic follow-up.
Discussion
Blood transfusion remains the most effective treatment to acutely increase Hb concentration in severely anemic patients. However, blood transfusions are not an option for patients who refuse blood products on the basis of personal preferences or religious beliefs. Several studies report the risks of severe anemia (Hb < 6 g/dL): end organ ischemia, multiorgan failure, and mortality as high as 100% at extremely low Hb concentrations (1, 6, (10) (11) (12) . Mortality increases as an inverse function of Hb concentration (1,6,13). The odds of death increase 2.5 fold for every 1-g/dL decrease in Hb concentration <8 g/dL.
HBOC-201 has an oxygen-carrying capacity similar to that of native Hb and can effectively increase the THb concentration (THb = [RBC Hb] + [free Hb]) in circulation, thereby increasing the oxygen-carrying capacity of blood. However, because HBOC-201 is iso-oncotic, it also expands the blood volume by the volume infused. Although increasing circulatory volume within safe limits would result in greater venous return and cardiac output, HBOC-201-like all cell-free Hb solutions-scavenges nitric oxide, inducing mild arterial vasoconstriction that offsets the potential effect of volume expansion to increase cardiac output. Consequently, cardiac output is often slightly reduced following HBOC-201 administration. Despite this, blood flow and convective oxygen delivery are maintained to vital organs, and oxygenation remains normal during HBOC-201 administration (12, (14) (15) (16) (17) .
Because HBOC-201 has lower oxygen affinity (p50 = 40 mmHg) than native human Hb (27 mmHg), it loads a higher fraction of oxygen than native Hb and facilitates oxygen exchange between RBCs and between RBCs and tissues (18) . Because of its small size compared with RBCs and dissolution in the plasma phase, HBOC-201 also decreases diffusion distances between RBCs and has greater proximity to endothelial cells than do RBCs. These properties collectively facilitate diffusive oxygen delivery to tissues that, in turn, increase oxygen extraction from blood and improve tissue oxygenation (18, 19) . In fact, under conditions of severe anemia, HBOC-201 has been shown to dose-dependently increase skeletal muscle partial pressure of oxygen with a threefold higher potency, gram for gram, than RBC Hb (17) (18) (19) . In models of severe trauma and hemorrhagic shock, generally characterized by anemia and survival <50% in asanguinous control treatment groups, the disparity in survival between animals treated with HBOC-201 (85% survival) and animals resuscitated with Hb-free crystalloid or colloid solutions (14% survival) was profound (17) (18) (19) (20) .
No randomized clinical trial to evaluate HBOC-201 against an asanguinous treatment arm has been conducted to date. However, analysis of 54 compassionate use cases characterized by severe anemia indicates that the probability of survival is increased by early administration of HBOC-201 to acutely bleeding and hemolyzing patients (3).
The three most common adverse effects observed with HBOC-201 are increases in arterial blood pressure; elevated plasma liver enzyme concentrations, primarily due to colorimetric interference; and development of methemoglobinemia. Blood pressure increases are attributable to the well-known nitric oxide scavenging properties of HBOCs and are generally mild to moderate and transient. Increases in BP are easily controlled by standard antihypertensive therapy, and the rise in blood pressure in the current patient was, in fact, controlled by intravenous administration of a calcium channel blocker (4, 20) . In addition, the intense red coloration of HBOC-201 can interfere with laboratory tests based on colorimetric methodologies. Elevated MetHb elevations occurred in the current patient and responded to the administration of methylene blue infusion. An increase in metHb is an expected finding with administration of HBOC-201. In the absence of sufficient metHb reductase, which is contained in RBCs and not present in HBOC-201, reduction of metHb is slow. Thus, metHb concentrations in blood may increase. Although metHb per se has no intrinsic toxicity, it does not carry oxygen and can affect oxygen delivery, particularly at very low hematocrit levels, thus pharmacological reduction of metHb with methylene blue or ascorbic acid is prudent at metHb concentrations >15% of THb. (19, 20) . A randomized, multicenter, RBC-controlled transfusion trial in noncardiac surgery patients showed that infusion of HBOC-201 resulted in 43% avoidance of RBC transfusion without notable difference in mortality and serious adverse events (2) . A definitive conclusion is precluded because the study was underpowered to detect an incidence of 1-3%.
The patient, throughout his intensive care unit stay, responded well to HBOC-201 infusion and experienced no liver, kidney, or pancreatic adverse effects-a transient side effect profile reported previously in some patients but found to be unaccompanied by clinical pathology. The transplanted grafts in this patient functioned well, and creatinine levels normalized to 0.8 mg/dL. The patient continued to do well at 30 days after transplant.
Conclusion
This case is the first report of HBOC-201 for the management of severe anemia in an organ transplant recipient and the first use of an HBOC in a double solid organ transplant recipient. HBOC-201 was a critical element in the overall treatment strategy for this patient, preventing the devastating morbidity of hypoxia and possible death that would have otherwise occurred secondary to severe anemia. As illustrated by this case, HBOC-201 may serve as a lifesaving intervention in a subgroup of patients with severe symptomatic anemia that refuse blood transfusion and should be considered as a bridging alternative until the patient's hematocrit has been restored to a safe level.
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